Organization
COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 CNRS
1 abstract
Abstract
Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?Org: COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 CNRS, CRCM, Hôpital Nord, SMARTc Centre de Recherche en Cancérologie de Marseille Inserm U1068, Multidisciplinary Oncology and Therapeutic Innovations,